Last updated: November 13, 2024
Sponsor: Vastra Gotaland Region
Overall Status: Active - Recruiting
Phase
N/A
Condition
Pain (Pediatric)
Treatment
N/AClinical Study ID
NCT06081439
ImmunoGraves wp2
Ages 18-72 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Recently diagnosed Graves' disease
Positive thyroid stimulating hormone (TSH)-receptor antibodies (TRAb)
Thyroid hormones above the upper reference limit
Inclusion within three weeks after start of antithyroid drugs
Controls: Matched for gender and age
Exclusion
Exclusion Criteria:
Person unable to follow protocol as with psychosis, dementia or not able to answerquestionnaires in Swedish.
Recidive of Graves' disease
Pregnancy
Controls: -Thyroid disease
- Neurological disease
Study Design
Total Participants: 430
Study Start date:
September 12, 2019
Estimated Completion Date:
December 20, 2025
Connect with a study center
Endokrina Forskningsenheten, Sahlgrenska University Hospital
Gothenburg, 41346
SwedenActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.